METRO-BIBF: Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer

Sponsor

University College, London (Other)

Overall Status

Completed

CT.gov ID

NCT01610869

Collaborator

Boehringer Ingelheim (Industry)

117

Enrollment

Locations

Arms

41.4

Actual Duration (Months)

7.3

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective is to explore the efficacy and safety of an all oral combination of BIBF 1120 (an inhibitor of angiogenic signalling) and metronomic cyclophosphamide in patients with multiply-relapsed advanced ovarian cancer, who have completed a minimum of two lines of previous chemotherapy and who for any reason are not suitable for further 'standard' intravenous chemotherapy treatments.

Condition or Disease	Intervention/Treatment	Phase
Ovarian Cancer Fallopian Tube Cancer	Drug: BIBF 1120	Phase 2

Detailed Description

A randomised placebo controlled double blind multi-centre phase II trial: BIBF 1120 200mg bd plus 100mg daily of oral cyclophosphamide (experimental arm) or oral cyclophosphamide 100mg daily plus placebo (control arm). Patients will receive oral BIBF 1120 and cyclophosphamide or cyclophosphamide and placebo continuously until disease progression or unacceptable toxicity.

Study Design

Study Type:

Interventional

Actual Enrollment :

117 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Care Provider, Investigator)

Primary Purpose:

Treatment

Official Title:

Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer

Actual Study Start Date :

Aug 1, 2014

Actual Primary Completion Date :

Jan 11, 2018

Actual Study Completion Date :

Jan 11, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cyclophosphamide and BIBF-1120 Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.	Drug: BIBF 1120 Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo. Other Names: BIBF 1120 brand name: Nintedanib.
Placebo Comparator: Cyclophosphamide and placebo Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.	Drug: BIBF 1120 Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo. Other Names: BIBF 1120 brand name: Nintedanib.

Arm

Intervention/Treatment

Experimental: Cyclophosphamide and BIBF-1120

Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.

Drug: BIBF 1120

Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.

Other Names:

BIBF 1120 brand name: Nintedanib.

Placebo Comparator: Cyclophosphamide and placebo

Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.

Drug: BIBF 1120

Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.

Other Names:

BIBF 1120 brand name: Nintedanib.

Outcome Measures

Primary Outcome Measures

Overall survival [After follow-up is complete (year 3-4 of the trial)]
To be measured in days, from the date of randomisation to the date of death.

Secondary Outcome Measures

Quality of life and qualitative health data [After follow-up is complete (year 3-4 of the trial)]
Health questionnaires which record qualitative health data on the patient perspective of their illness and treatment. This will be measured on a 6 weekly basis, from baseline to the end of treatment.
Adverse events for all patients [After follow-up is complete (year 3-4 of the trial)]
Adverse events will be collected for patients in both groups during treatment and the groups compared during analysis. This will be measured on a 6 weekly basis, from baseline to the end of treatment. The first 12 patients will be assessed on a 3 weekly basis, from baseline to end of treatment.
Progression free survival [After follow-up is complete (year 3-4 of the trial)]
Progression free survival will be determined by measurement of tumour size using RECIST 1.1 at progression or by a rise in CA-125 tumour marker. Measured from the date of randomisation until date of confirmed disease progression. Tumour assessment carried out on 3 monthly basis, CA-125 carried out on 6 weekly basis.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Female subjects, ≥18 years, histologically proven recurrent advanced epithelial ovarian, fallopian tube or primary peritoneal carcinomas
Have either undergone a hysterectomy or bilateral oophorectomy/salpingectomy and/or have been postmenopausal for 24 consecutive months (i.e. who have not had menses at any time in the preceding 24 consecutive months without an alternative medical cause)
Performance status 0-2
Adequate organ function
Life expectancy >6 weeks
Has received 2 or more lines of chemotherapy for ovarian cancer and patient is platinum resistant or platinum intolerant or not suitable for any further standard intravenous chemotherapy
No previous oral cyclophosphamide, nintedanib, or other tyrosine kinase inhibitors such as cediranib but patients can have received anti-VEGF therapies such as bevacizumab as they will be stratified for this
Measurable lesions according to RECIST 1.1 criteria or serum CA125 levels for evaluation by GCIG CA125 criteria are welcomed but not a prerequisite for inclusion as response will only be assessed for those with evaluable disease
Able to give written informed consent and to complete QoL

Exclusion Criteria

Carcinosarcoma or malignant tumour of non-epithelial origin (e.g. germ cell tumour, sex cord-stromal tumour) of the ovary, fallopian tube or peritoneum
Clinically relevant non-healing wound, ulcer (intestinal tract, skin) or bone fracture
Symptoms or signs of gastrointestinal obstruction requiring parenteral nutrition or hydration or any other GI disorders or abnormalities that would interfere with drug absorption or inability to take oral medication
Active brain metastases (i.e. symptoms deteriorating, changing condition in < 4 weeks) or leptomeningeal disease. Trial entry is allowed if the brain metastases are stable (asymptomatic or condition stable for > 4 weeks).
Dexamethasone for brain metastases is allowed if administered as stable dose for > 4 weeks before randomisation (if < 4 weeks then the patient is not eligible)
Clinically relevant therapy-related toxicity from previous chemotherapy and radiotherapy
History of major thromboembolic event within the last 6 months, such as pulmonary embolism or proximal deep vein thrombosis, unless on stable therapeutic anticoagulation (>3 months if on warfarin, PT / INR needs to be monitored regularly as per table 8.1 in protocol)
Known inherited or acquired bleeding disorder
Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within the past 6 months, congestive heart failure > NYHA II, severe peripheral vascular disease, significantly relevant pericardial effusion
History of a cerebral vascular accident, transient ischemic attack or subarachnoid hemorrhage within the past 6 months
Radiographic evidence of cavitating or necrotic tumours with invasion of adjacent major blood vessels
Laboratory values indicating an increased risk for adverse events:

calculated GFR < 45 ml/min. Sites can use any calculation method according to local practice.
absolute neutrophil count (ANC) < 1.5x109/L
platelets < 100 x109/L
haemoglobin < 90 g/L
proteinuria CTCAE 2 or greater
total bilirubin > x 2 ULN
ALT and/or AST > 1.5 x ULN
unless liver metastases present when ALT or AST > 2.5 ULN
International normalized ratio (INR) > 2 or activated partial thromboplastin time (APTT) >1.5 x ULN in the absence of therapeutic anticoagulation. INR > 4 or APTT

2.5 x ULN in presence of therapeutic anticoagulation

Serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal or antiviral therapy), including hepatitis B and/or C infection, HIV- infection
Poorly controlled diabetes mellitus or patient on sulphonylurea-type hypoglycaemics (e.g. gliclazide) as main diabetic control (as contraindicated with cyclophosphamide)
Previous breast cancer patients are permitted only if diagnosis and any chemotherapy treatment for this was > 5 years previously and there is no evidence of metastatic breast cancer at trial entry (Please contact UCL CTC / CI if patient still on hormone treatment for breast cancer).
Other malignancy diagnosed within the past 5 years. In exception to this rule, the following malignancies may be included:

non-melanoma skin cancer (if adequately treated)
cervical carcinoma in situ (if adequately treated)
prior or synchronous endometrial cancer (if adequately treated), provided all of the following criteria are met: G1 or G2, no LVSI and FIGO (2010) stage IA only

Serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease or a laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study
Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule e.g. active alcohol or drug abuse
Any contraindications for therapy with cyclophosphamide, e.g. a history of severe hypersensitivity reactions to listed excipients for cyclophosphamide treatment with other investigational drugs
Patients should not commence trial treatment within 6 weeks of any major surgical procedure
Participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial
Chemotherapy, including immunotherapy or monoclonal antibody treatment (VEGF) within 4 weeks of starting study treatment
Hormone treatment for ovarian cancer within 2 weeks of starting study treatment (ongoing HRT is allowable)
Any previous tyrosine kinase inhibitor treatment that has predominantly anti-angiogenic action
Radiotherapy within 3 months not allowed except when given for symptom control >28d previously. All patients receiving any radiotherapy will require evidence of recurrent ovarian cancer outside the irradiated field either on imaging or via rising CA125
Hypersensitivity to nintedanib, peanut or soya, or to any of the excipients of nintedanib

Contacts and Locations

Locations

	Site	City	State	Country
1	Kent Oncology Centre	Maidstone	Kent	United Kingdom
2	Beatson West of Scotland Cancer Centre	Glasgow	Scotland	United Kingdom
3	Velindre Hospital	Cardiff	Wales	United Kingdom
4	Royal United Hospital	Bath		United Kingdom
5	Addenbrookes Hospital	Cambridge		United Kingdom
6	Royal Derby Hospital	Derby		United Kingdom
7	Royal Surrey County Hospital	Guildford		United Kingdom
8	St James's University Hospital	Leeds		United Kingdom
9	Clatterbridge Centre for Oncology	Liverpool		United Kingdom
10	Mount Vernon Hospital	London		United Kingdom
11	Royal Marsden Hospital	London		United Kingdom
12	St Bartholomew's Hospital	London		United Kingdom
13	University College London Hospital (UCLH)	London		United Kingdom
14	Christie Hospital	Manchester		United Kingdom
15	Churchill Hospital	Oxford		United Kingdom
16	Wexham Park Hospital	Slough		United Kingdom